PBX Stock Overview
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ProBiotix Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.05 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | -0.19 |
| 1 Month Change | -9.09% |
| 3 Month Change | -28.57% |
| 1 Year Change | -23.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 2.8% |
| 1Y | -23.1% | -27.7% | 1.1% |
Return vs Industry: PBX exceeded the UK Biotechs industry which returned -27.7% over the past year.
Return vs Market: PBX underperformed the UK Market which returned 1.1% over the past year.
Price Volatility
| PBX volatility | |
|---|---|
| PBX Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PBX's share price has been volatile over the past 3 months.
Volatility Over Time: PBX's weekly volatility has decreased from 11% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Steen Andersen | probiotixhealth-ir.com |
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions. The company was formerly known as ProBiotix Health Limited and changed its name to ProBiotix Health Plc in February 2022. The company was incorporated in 2021 and is based in Wakefield, the United Kingdom.
ProBiotix Health Plc Fundamentals Summary
| PBX fundamental statistics | |
|---|---|
| Market cap | UK£6.08m |
| Earnings (TTM) | -UK£476.00k |
| Revenue (TTM) | UK£1.56m |
3.9x
P/S Ratio-12.8x
P/E RatioIs PBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBX income statement (TTM) | |
|---|---|
| Revenue | UK£1.56m |
| Cost of Revenue | UK£710.00k |
| Gross Profit | UK£849.00k |
| Other Expenses | UK£1.33m |
| Earnings | -UK£476.00k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 54.46% |
| Net Profit Margin | -30.53% |
| Debt/Equity Ratio | 0% |
How did PBX perform over the long term?
See historical performance and comparison